CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains ...

Jefferies sees Arbutus (NASDAQ:ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE) ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

Moderna stock was on track to see a weekly gain of 10% as of Wednesday following the first reported bird flu death in the US.

In rural Virginia, a single land transfer is a first step toward correcting a long history of land loss for Black Southern ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of CureVac are trading higher by 15% during Monday's session. The stock is gaining following a CDC report highlighting ...